These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 2144363)

  • 21. Coactivator requirements for p53-dependent transcription in the yeast Saccharomyces cerevisiae.
    Yousef AF; Xu GW; Mendez M; Brandl CJ; Mymryk JS
    Int J Cancer; 2008 Feb; 122(4):942-6. PubMed ID: 17957787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
    Bartek J; Iggo R; Gannon J; Lane DP
    Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
    Shimada A; Kato S; Enjo K; Osada M; Ikawa Y; Kohno K; Obinata M; Kanamaru R; Ikawa S; Ishioka C
    Cancer Res; 1999 Jun; 59(12):2781-6. PubMed ID: 10383130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional activation by DNA-binding derivatives of HSV-1 VP16 that lack the carboxyl-terminal acidic activation domain.
    Popova B; Bilan P; Xiao P; Faught M; Capone JP
    Virology; 1995 May; 209(1):19-28. PubMed ID: 7747469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.
    Addison C; Jenkins JR; Stürzbecher HW
    Oncogene; 1990 Mar; 5(3):423-6. PubMed ID: 2156209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
    Brown DR; Deb D; Frum R; Hickes L; Munoz R; Deb S; Deb SP
    Int J Oncol; 2001 Mar; 18(3):449-59. PubMed ID: 11179471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate.
    Khochbin S; Lawrence JJ
    EMBO J; 1989 Dec; 8(13):4107-14. PubMed ID: 2480234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53: oncogene or anti-oncogene?
    Lane DP; Benchimol S
    Genes Dev; 1990 Jan; 4(1):1-8. PubMed ID: 2137806
    [No Abstract]   [Full Text] [Related]  

  • 29. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses.
    Levine AJ
    Virology; 1990 Aug; 177(2):419-26. PubMed ID: 2142553
    [No Abstract]   [Full Text] [Related]  

  • 30. Mammalian two-hybrid system: a complementary approach to the yeast two-hybrid system.
    Luo Y; Batalao A; Zhou H; Zhu L
    Biotechniques; 1997 Feb; 22(2):350-2. PubMed ID: 9043710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potential transcriptional activation element in the p53 protein.
    O'Rourke RW; Miller CW; Kato GJ; Simon KJ; Chen DL; Dang CV; Koeffler HP
    Oncogene; 1990 Dec; 5(12):1829-32. PubMed ID: 2284102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through P53 stabilization.
    Ha SA; Shin SM; Lee YJ; Kim S; Kim HK; Namkoong H; Lee H; Lee YS; Cho YS; Park YG; Jeon HM; Oh C; Kim JW
    Int J Cancer; 2008 Feb; 122(3):501-8. PubMed ID: 17943721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity.
    Maeda Y; Seidel SD; Wei G; Liu X; Sladek FM
    Mol Endocrinol; 2002 Feb; 16(2):402-10. PubMed ID: 11818510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase.
    Merrill GF; Dowell P; Pearson GD
    Cancer Res; 1999 Jul; 59(13):3175-9. PubMed ID: 10397262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The JUN oncoprotein, a vertebrate transcription factor, activates transcription in yeast.
    Struhl K
    Nature; 1988 Apr; 332(6165):649-50. PubMed ID: 3128739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
    Barel M; Fiandino A; Lyamani F; Frade R
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations that alter both localization and production of a yeast nuclear protein.
    Silver PA; Chiang A; Sadler I
    Genes Dev; 1988 Jun; 2(6):707-17. PubMed ID: 3138162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products.
    Levine AJ; Momand J
    Biochim Biophys Acta; 1990 Jun; 1032(1):119-36. PubMed ID: 2142001
    [No Abstract]   [Full Text] [Related]  

  • 40. The tissue-specific mammalian transcription factor, Pit-1, activates transcription in Saccharomyces cerevisiae.
    Ding Y; Lu W; Roberson MS; Moye-Rowley WS; Maurer RA
    Mol Endocrinol; 1991 Sep; 5(9):1239-45. PubMed ID: 1770950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.